Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 1
2012 2
2017 2
2018 2
2019 2
2020 1
2022 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodríguez-Seguel E, Mateos B, Rodríguez M, Rosales Zabal JM, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Badia Aranda E, Hernández-Guerra M, Maté CJ, González-Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, Buti M. Ruiz-Cobo JC, et al. Among authors: rosales zabal jm. Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2. Aliment Pharmacol Ther. 2024. PMID: 38695095
[Syphilitic hepatitis: case report].
Albandea Moreno C, Aguilar Urbano VM, Rivera Irigoin R, Gonzalo Marín J, Rosales Zabal JM, Moreno García A, Fernández Pérez F, García Fernández G, Pérez Aisa A, Méndez Sánchez IM, Sánchez Cantos A. Albandea Moreno C, et al. Among authors: rosales zabal jm. Rev Esp Enferm Dig. 2009 Nov;101(11):813-4. doi: 10.4321/s1130-01082009001100011. Rev Esp Enferm Dig. 2009. PMID: 20001160 Free article. Spanish. No abstract available.
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED Collaborators. Howe AYM, et al. JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May. JHEP Rep. 2022. PMID: 35434589 Free PMC article.
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). de Salazar A, et al. Among authors: rosales zabal jm. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. J Antimicrob Chemother. 2020. PMID: 32772078
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-Gallego MJ, Rosales-Zábal JM, García F; GEHEP-004 Study Group. Pérez AB, et al. Among authors: rosales zabal jm. J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279901
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Hernández-Conde M, et al. Among authors: rosales zabal jm. J Viral Hepat. 2019 Jan;26(1):55-64. doi: 10.1111/jvh.13008. Epub 2018 Oct 25. J Viral Hepat. 2019. PMID: 30265418
[Acute mesenteric ischemia: importance of an early diagnosis].
Albandea Moreno C, Aguilar Urbano VM, Gonzalo Marín J, Rosales Zabal JM, Rivera Irigoín R, Fernández Gutiérrez Del Alamo F, Pérez Aísa A, Sánchez Cantos A. Albandea Moreno C, et al. Among authors: rosales zabal jm. Rev Esp Enferm Dig. 2009 Sep;101(9):661-2. doi: 10.4321/s1130-01082009000900016. Rev Esp Enferm Dig. 2009. PMID: 19803675 Free article. Spanish. No abstract available.
15 results